Petros Pharmaceuticals, Inc. (PTPI)
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
$3.27M
Mr. John D. Shulman
24.00
New York, NY
Dec 02, 2020
-0.06
$-6.16
0.93
1.65
-6,229.97%
-0.01
0.22
0.72
1.25
-835.45%
-1,459.20%
Similar stocks (9)
Alimera Sciences, Inc.
ALIM
Alpha Teknova, Inc.
TKNO
Lifecore Biomedical, Inc.
LFCR
Cumberland Pharmaceuticals Inc.
CPIX
Guardion Health Sciences, Inc.
GHSI
Agile Therapeutics, Inc.
AGRX
Shuttle Pharmaceuticals Holdings, Inc.
SHPH
Sonoma Pharmaceuticals, Inc.
SNOA
Evoke Pharma, Inc.
EVOK
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (9)
Alimera Sciences, Inc.
ALIM
Alpha Teknova, Inc.
TKNO
Lifecore Biomedical, Inc.
LFCR
Cumberland Pharmaceuticals Inc.
CPIX
Guardion Health Sciences, Inc.
GHSI
Agile Therapeutics, Inc.
AGRX
Shuttle Pharmaceuticals Holdings, Inc.
SHPH
Sonoma Pharmaceuticals, Inc.
SNOA
Evoke Pharma, Inc.
EVOK
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%